Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36 for drug discovery and mechanism of action (MOA) research

Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Clervonafusp Alfa is consisting of immunoglobulin G1-kappa, cell-penetrating humanized Fab fragment targeting the equilibrative nucleoside transporter 2 (ENT2), fused with a human lysosomal α-glucosidase fragment, glycoform alfa. It is used to treat Pompe disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-783-1mg	1mg	3090
GMP-Bios-INN-783-10mg	10mg	Inquiry
GMP-Bios-INN-783-100mg	100mg	Inquiry
GMP-Bios-INN-783-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Clervonafusp Alfa Biosimilar, Fusion Protein targeting SLC29A2/ENT2 fused with human GAA (glucosidase alpha, acid, lysosomal alpha-glucosidase )(Pr67-952) (1:2) Enzyme substitute: Recombinant therapeutic protein targeting DER12/HNP36
INN Name	Clervonafusp Alfa
Target	SLC29A2
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	F(ab')2 - G1 - kappa
VD LC	F(ab')2 - G1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Valerion Therapeutics, LLC. (Concord MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0